)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Xeris Biopharma
Xeris Biopharma (XERS) investor relations material
Xeris Biopharma Barclays 28th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Barclays 28th Annual Global Healthcare Conference summary11 Mar, 2026
Company overview and product portfolio
Operates as a fast-growing commercial biopharma with three marketed products: Gvoke, KEVEYIS, and RECORLEV.
Gvoke targets hypoglycemia, KEVEYIS addresses primary periodic paralysis, and RECORLEV treats hypercortisolemia/Cushing's syndrome.
Pipeline includes XP-8121, a once-weekly SubQ levothyroxine for hypothyroidism, phase III-ready and expected to start trials this year.
Financial performance and growth
Achieved $292 million in revenue for 2025, representing 44% growth and surpassing guidance.
Delivered $60 million in adjusted EBITDA and reported net income for the full year.
Transitioned to self-funding strategy, supporting both pipeline and future growth.
Product performance and market dynamics
RECORLEV experienced over 100% growth for two consecutive years, driven by increased diagnosis and expanded sales force.
Gvoke continues steady growth, focusing on increasing patient adoption among those at risk for hypoglycemia.
KEVEYIS remained resilient despite generic competition, returning to growth in 2025 with patient support services offsetting pricing pressures.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xeris Biopharma
- FY2025 revenue surged 44% YoY, with XP-8121 poised to drive future multi-billion growth.XERS
Corporate presentation11 Mar 2026 - Record 2025 results and profitability set the stage for over 30% growth in 2026.XERSQ4 20252 Mar 2026
- Q2 revenue up 26% to $48.1M; guidance raised amid strong Gvoke and Recorlev growth.XERSQ2 20242 Feb 2026
- Raised guidance follows 25% revenue growth, strong product performance, and expanding partnerships.XERSJefferies 2024 Global Healthcare Conference1 Feb 2026
- Strong growth, disciplined spending, and breakeven targeted for 2025 amid robust product momentum.XERSH.C. Wainwright 26th Annual Global Investment Conference21 Jan 2026
- Record Q3 revenue, raised guidance, and strong pipeline progress despite higher net loss.XERSQ3 202415 Jan 2026
- Strong growth in rare disease and diabetes markets, with a promising hypothyroid pipeline asset.XERSPiper Sandler 36th Annual Healthcare Conference12 Jan 2026
- Guiding over 30% revenue growth, with pipeline and platform innovation driving future value.XERSLeerink Global Healthcare Conference 202526 Dec 2025
- Strong product growth and pipeline innovation position the business for profitability in 2025.XERSOppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202523 Dec 2025
Next Xeris Biopharma earnings date
Q1 20267 May, 2026
Xeris Biopharma
Next Xeris Biopharma earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage